Beatrice Tien-Yi Wang

Title: Beatrice Tien-Yi Wang: Innovator in Biopharmaceuticals

Introduction

Beatrice Tien-Yi Wang is a prominent inventor based in Mountain View, CA (US). She has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative binding molecules. With a total of three patents to her name, her work has the potential to impact therapeutic strategies for various diseases.

Latest Patents

One of her latest patents is titled "Multimeric bispecific binding molecules specific for CD20 and CD3." This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells. Another notable patent is "Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof." This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.

Career Highlights

Beatrice has worked with notable companies in the biopharmaceutical sector, including IgM Biosciences, Inc. and IgM Biosciences A/S. Her expertise in the field has allowed her to contribute to groundbreaking research and development efforts.

Collaborations

Throughout her career, Beatrice has collaborated with esteemed colleagues such as Bruce Alan Keyt and Ramesh Baliga. These collaborations have further enhanced her innovative work and expanded the impact of her inventions.

Conclusion

Beatrice Tien-Yi Wang is a trailblazer in the biopharmaceutical industry, with her patents paving the way for new therapeutic approaches. Her contributions are invaluable to the advancement of medical science and patient care.